Literature DB >> 12417130

Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.

Kathryn Turton1, John A Chaddock, K Ravi Acharya.   

Abstract

The toxic products of the anaerobic bacteria Clostridium botulinum, Clostridium butyricum, Clostridium barati and Clostridium tetani are the causative agents of botulism and tetanus. The ability of botulinum neurotoxins to disrupt neurotransmission, often for prolonged periods, has been exploited for use in several medical applications and the toxins, as licensed pharmaceutical products, now represent the therapeutics of choice for the treatment for several neuromuscular conditions. Research into the structures and activities of botulinum and tetanus toxins has revealed features of these proteins that might be useful in the design of improved vaccines, effective inhibitors and novel biopharmaceuticals. Here, we discuss the relationships between structure, mechanism of action and therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417130     DOI: 10.1016/s0968-0004(02)02177-1

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  87 in total

1.  Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity.

Authors:  Brent Segelke; Mark Knapp; Saloumeh Kadkhodayan; Rod Balhorn; Bernhard Rupp
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-23       Impact factor: 11.205

2.  Structures of engineered Clostridium botulinum neurotoxin derivatives.

Authors:  Geoffrey Masuyer; Patrick Stancombe; John A Chaddock; K Ravi Acharya
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-11-25

3.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

4.  A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.

Authors:  Christiane G Frick; Heidrun Fink; Manfred Blobner; Jeevendra Martyn
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

5.  In situ scanning probe microscopy studies of tetanus toxin-membrane interactions.

Authors:  Andrea L Slade; Joseph S Schoeniger; Darryl Y Sasaki; Christopher M Yip
Journal:  Biophys J       Date:  2006-09-22       Impact factor: 4.033

Review 6.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

7.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 8.  Emerging therapies for chronic migraine.

Authors:  Alberto Proietti Cecchini; Licia Grazzi
Journal:  Curr Pain Headache Rep       Date:  2014-04

9.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.

Authors:  Patrícia A E Abreu; Patrícia A Miyasato; Mônica M Vilar; Waldely O Dias; Paulo L Ho; Míriam Tendler; Ana L T O Nascimento
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.